Arrowstreet Capital’s ImmunityBio IBRX Stock Holding History

Arrowstreet Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-65,700	Closed	-$938K	–	1716
2021 Q2	$938K	Buy	+65,700	New	+$1.09M	﹤0.01%	1556

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Arrowstreet Capital's IBRX Position: Q3 2021 in Review

Arrowstreet Capital sold out of ImmunityBio (IBRX) in Q3 2021, closing a stake of 65,700 shares — an estimated $938K sold.

Arrowstreet Capital first reported a position in IBRX in Q2 2021 and held it in 1 quarter. The position peaked at $938K in Q2 2021. 126 funds tracked by Wall St. Rank hold IBRX as of Q3 2021.

Arrowstreet Capital reported no remaining ImmunityBio position as of Q3 2021 after selling out during the quarter.
Arrowstreet Capital sold 65,700 ImmunityBio shares in Q3 2021, an estimated $938K.
Arrowstreet Capital first reported a position in ImmunityBio in Q2 2021 and held it in 1 quarter.
Arrowstreet Capital's ImmunityBio position peaked at $938K in Q2 2021.
126 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2021.

Based on Arrowstreet Capital's 13F filing for Q3 2021, filed 12 Nov 2021.